-
December 2018 Corporate Presentation
-
<strong>The Liver Meeting, AASLD, November 2018 </strong><br> <i>Blood Ammonia Levels are Labile and Responsive to Protein Intake in Patients with Compensated Cirrhosis without Overt Hepatic Encephalopathy</i>
-
<i>Genetically engineered E. coli Nissle attenuates hyperammonemia in two experimental models of hepatic encephalopathy</i>
-
November 10, 2018.<br>Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting <br><i>Development of a STING Agonist-producing Synthetic Biotic™ Medicine to Activate Innate and Adaptive Immunity and Drive Antitumor Immune Responses</i>
-
<i>Development of Synthetic Biotic Medicines in Oncology Presentation</i><br> <i>Slides from Synlogic Investor and Analyst Presentation at SITC 2018</i><br> <i>November 10, 2018</i>
-
<i>Metabolic Modulation of the Tumor Microenvironment using Synthetic Biotic™ Medicines</i>
-
2018 Annual meeting of the American Association for Cancer Research (AACR) April 16, 2018<br> <i>Activation of innate and adaptive immunity via combinatorial immunotherapy using Synthetic Biotic™ Medicines</i>
-
The International Liver Congress™ 2018 (EASL) : April 14th , 2018 <br> <i>Tolerability and Kinetics of SYNB1020 in a Phase 1, First-in-human, Healthy Adult Volunteer Study</i>
-
<i> June 3, 2018. <br> Basic Science Plenary Session, <br>Digestive Disease Week® (DDW) </i>
-
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria
-
<i>June 11, 2018. <br/> Plenary Session, Precision Microbiology, annual meeting of the American Society for Microbiology (ASM Microbe 2018) <br/>An Engineered E. coli Nissle for the treatment of Phenylketonuria (PKU)</i>
-
<i>Using Synthetic Biotic Medicines to Activate Innate and Adaptive Immunity and Drive Antitumor Immune Responses</i>
-
June 20 - 23, 2018. <br> Federation of Clinical Immunology Societies (FOCIS 2018) <br> <i>A Synthetic Biology Approach for the Treatment of Cancer and Inflammation,</i>